NCT06383325

Brief Summary

Detection of hepatotoxcicity in acute leukemia and study the outcome of acute leukemia patients that suffer from hepatic toxiciyt

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2024

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 22, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 25, 2024

Completed
6 days until next milestone

Study Start

First participant enrolled

May 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2025

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2025

Completed
Last Updated

April 25, 2024

Status Verified

April 1, 2024

Enrollment Period

1 year

First QC Date

April 22, 2024

Last Update Submit

April 22, 2024

Conditions

Liver Toxicity, Chemically-Induced

Outcome Measures

Primary Outcomes (1)

  • Detection of hepatotoxcicity in acute leukemia during chemotherapy treatment

    Evaluation of liver function test to identfy hepatotoxicity during chemotherapy treatment

    3 months

Interventions

ChemotherapyCOMBINATION_PRODUCT

Detection of hepatotoxicity in acute leukemia patients during chemotherapy

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participants who will be diagnosed as acute leukemia and going to receive chemotherapy after

You may qualify if:

  • patients newly diagnosed with acute leukemia who are going to start chemotherapy treatment

You may not qualify if:

  • patients previously diagnosed Acute leukemia and started treatment or in post treatment follow up

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Mekonnen AT, Wondmeneh TG. Evaluation of liver function tests to identify hepatotoxicity among acute lymphoblastic leukemia patients who are receiving chemotherapy induction. Sci Rep. 2022 Aug 2;12(1):13215. doi: 10.1038/s41598-022-17618-w.

    PMID: 35918381BACKGROUND

MeSH Terms

Conditions

Chemical and Drug Induced Liver Injury

Interventions

Drug Therapy

Condition Hierarchy (Ancestors)

Liver DiseasesDigestive System DiseasesDrug-Related Side Effects and Adverse ReactionsChemically-Induced DisordersPoisoning

Intervention Hierarchy (Ancestors)

Therapeutics

Central Study Contacts

Nada mohamed hamada Hamada wahba

CONTACT

01140476425Nm3390103@gmail.com

Enas Ahmed Reda alkareemy, Proffesor

CONTACT

01000004303alkareemy@aun.edu.eg

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

April 22, 2024

First Posted

April 25, 2024

Study Start

May 1, 2024

Primary Completion

May 1, 2025

Study Completion

August 1, 2025

Last Updated

April 25, 2024

Record last verified: 2024-04